Although the 54 ovarian cancer patients included in the latter study had detectable somatic mutations in their plasma ctDNA, only one somatic mutation was detected in each patient, and 46 (85%) patients had TP53 mutations. This evidence concerns the gene TP53 and ovarian carcinoma.